1-15 of 175
IL-23 Inhibitors Show Broad PsA Control, with Important Gaps Remaining
Living RheumIL-23 Inhibitors Show Broad PsA Control, with Important Gaps Remaining
Understanding Difficult-to-Treat Axial Spondyloarthritis in Real-World Practice
Living RheumUnderstanding Difficult-to-Treat Axial Spondyloarthritis in Real-World Practice
The Cardiovascular Dimension of Psoriatic Arthritis
Living RheumThe Cardiovascular Dimension of Psoriatic Arthritis
Early Arthritis Insights from the CATCH Cohort
Living RheumEarly Arthritis Insights from the CATCH Cohort
Louis Bessette MD, FRCP(C), MSc
Spot the Difference: Acute vs. Subacute Cutaneous Lupus
Living RheumSpot the Difference: Acute vs. Subacute Cutaneous Lupus
Avery H. LaChance, MD, MPH, FAAD
Key Advances in Rheumatology at CCR East 2026
Living RheumKey Advances in Rheumatology at CCR East 2026
Louis Bessette MD, FRCP(C), MSc
- advertisement
Avery H. LaChance, MD, MPH, FAAD
Measuring What Matters in Psoriatic Arthritis
Living RheumMeasuring What Matters in Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD
Minimal Disease Activity: A Practical Target in Psoriatic Arthritis
Living RheumMinimal Disease Activity: A Practical Target in Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD
Aligning Patient and Physician Perspectives in Psoriatic Arthritis
Living RheumAligning Patient and Physician Perspectives in Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD
The Next Era of Psoriatic Arthritis Management
Living RheumThe Next Era of Psoriatic Arthritis Management
Laura Coates, MBChB, MRCP, PhD
Unpacking the Complexity of Psoriatic Arthritis
Living RheumUnpacking the Complexity of Psoriatic Arthritis
Lawrence H. Brent
- advertisement
Diagnosing Psoriatic Arthritis: A Real-World Case
Living RheumDiagnosing Psoriatic Arthritis: A Real-World Case
Lawrence H. Brent
Modern Approaches to Psoriatic Arthritis Management
Living RheumModern Approaches to Psoriatic Arthritis Management
Lawrence H. Brent
JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
Living RheumJAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
